{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+Optimization&page=8", "query": { "intervention": "Medication Optimization", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 205, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+Optimization&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+Optimization&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T13:59:16.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04009291", "title": "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypoparathyroidism", "Endocrine System Diseases", "Parathyroid Diseases" ], "interventions": [ { "name": "TransCon PTH", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo for TransCon PTH", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Ascendis Pharma A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2019-08-27", "completion_date": "2025-04-17", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 5, "location_summary": "Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Great Neck", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009291" }, { "nct_id": "NCT07604571", "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer" ], "interventions": [ { "name": "IEV407", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2026-05-28", "completion_date": "2032-06-08", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07604571" }, { "nct_id": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Gastroesophageal Junction Adenocarcinoma", "HER2 Low Breast Neoplasms", "HER2 Positive Breast Neoplasms", "Stomach Neoplasms", "Triple Negative Breast Neoplasms", "Metastatic Breast Cancer", "Metastatic Gastric Cancer", "Advanced Breast Cancer", "Advanced Gastric Cancer" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2024-05-20", "completion_date": "2029-07-28", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 77, "location_summary": "Tucson, Arizona • Orange, California • San Francisco, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157892" }, { "nct_id": "NCT07674771", "title": "Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer", "Castration Sensitive Prostate Cancer", "Metastatic Prostate Cancer", "Adaptive Radiotherapy" ], "interventions": [ { "name": "Drug: 68-Ga PSMA11", "type": "DRUG" }, { "name": "Adaptive stereotactic ablative radiotherapy (SABR)", "type": "RADIATION" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "Adaptive stereotactive ablative radiotherapy (SABR)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2026-10", "completion_date": "2029-06-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07674771" }, { "nct_id": "NCT07478887", "title": "Impact of the Corrie Lipids Digital Health Program on Lipid Optimization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Risk", "LDL-C", "Lipids", "Digital Health", "Implementation Science" ], "interventions": [ { "name": "Corrie Lipids Digital Health Program", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-06-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07478887" }, { "nct_id": "NCT01760889", "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 low dose range (40mg, 80mg, and 100mg)", "type": "DRUG" }, { "name": "SPD489 high dose range (120mg, 140mg and 160mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2013-02-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 4, "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more", "locations": [ { "city": "Miami Springs", "state": "Florida" }, { "city": "O'Fallon", "state": "Missouri" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760889" }, { "nct_id": "NCT02493777", "title": "A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "HLD200 methylphenidate hydrochloride (MPH) Capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ironshore Pharmaceuticals and Development, Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 125, "start_date": "2015-07", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 7, "location_summary": "Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Marshfield", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493777" }, { "nct_id": "NCT05405595", "title": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Standard of Care (Trifluridine/Tipiracil-Bevacizumab)", "type": "DRUG" }, { "name": "Standard of care (Fruquintinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2022-06-15", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405595" }, { "nct_id": "NCT04643002", "title": "Isatuximab in Combination With Novel Agents in RRMM - Master Protocol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plasma Cell Myeloma Refractory" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pegenzileukin", "type": "DRUG" }, { "name": "SAR439459", "type": "DRUG" }, { "name": "Belumosudil", "type": "DRUG" }, { "name": "Evorpacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2021-01-25", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04643002" }, { "nct_id": "NCT07128303", "title": "Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "GS-5319", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 476, "start_date": "2025-08-28", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-22T13:59:16.672Z", "location_count": 4, "location_summary": "Boston, Massachusetts • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128303" } ] }